Martin H. Huber Jr. - 21 Oct 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
President of R&D and CMO
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
21 Oct 2021
Net transactions value
$0
Form type
3
Filing time
21 Oct 2021, 20:40:26 UTC
Previous filing
17 Sep 2021
Next filing
05 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) 21 Oct 2021 Common Stock 134,797 $5.51 Direct F1
holding XLO Stock Option (right to buy) 21 Oct 2021 Common Stock 79,272 $5.89 Direct F2
holding XLO Stock Option (right to buy) 21 Oct 2021 Common Stock 77,786 $11.69 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on July 23, 2020 for 134,797 shares. On April 27, 2021, 25% of the shares underlying the option vested and the remainder shall vest in equal monthly installments thereafter until April 27, 2024.
F2 The option was granted on March 11, 2021 for 79,272 shares. On April 1, 2021, the shares underlying the option began vesting and shall continue vesting in equal monthly installments thereafter until March 1, 2025.
F3 The option was granted on August 23, 2021 for 77,786 shares. On September 1, 2021 the shares underlying the options began vesting and shall continue vesting in equal monthly installments thereafter until August 1, 2025.

Remarks:

Exhibit Index: 24.1 Power of Attorney